RBC Upgrades Pfizer to Sector Perform as Valuation Resets
RBC Capital Markets upgraded Pfizer from Underperform to Sector Perform, maintaining a $25 price target. The upgrade follows an 11% pullback from 2026 highs, which the brokerage says has brought valuation in line with expectations.
Key Numbers
RBC Capital Markets upgraded Pfizer Inc. (NYSE: PFE) to Sector Perform from Underperform, while maintaining its $25 price target, according to a research note.
Rating Change
- Previous Rating: Underperform
- New Rating: Sector Perform
- Price Target: $25 (unchanged)
Analyst Rationale
RBC analysts noted that the stock has pulled back roughly 11% from its 2026 highs, leading to a more balanced risk-reward profile. They believe the current valuation has reset, reducing the downside risks they previously highlighted. The brokerage said the stock may have found a more balanced risk-reward profile after the sharp decline.
Context
Pfizer shares have underperformed this year, falling 11% from their 2026 highs. No other analysts have commented on the upgrade yet. Investors are watching for pipeline catalysts that could drive future performance.
What to Make of It
RBC's upgrade reflects a valuation adjustment rather than a fundamental change in Pfizer's outlook. Investors should monitor pipeline developments and future guidance before making decisions.
Frequently Asked Questions
Found this useful? Share it